Bruker Announces One-Hundred Dollar, Deep, High-Accuracy Plasma Proteome; Advances Glycoproteomics and Metaproteomics
Bruker (Nasdaq: BRKR) announces significant advancements in 4D-Proteomics at the 23rd Human Proteome Organization World Congress. Key developments include:
1. Enhanced specificity and proteome coverage using diagonal-PASEF.
2. Achievement of a one-hundred dollar deep, high-accuracy plasma proteome analysis.
3. Introduction of high-sensitivity plasma glycopeptide analysis on timsTOF Ultra 2.
4. Increased peptide and protein identifications with ML-enhanced TIMSrescore.
5. Introduction of multiomics visualization and insights for proteomics and metabolomics.
These advancements enable robust, unbiased, and affordable proteomics with high-specificity protein identification and quantification, suitable for large-scale plasma proteomics studies.
Bruker (Nasdaq: BRKR) annuncia importanti progressi nella 4D-Proteomica in occasione del 23° Congresso Mondiale dell'Organizzazione del Proteoma Umano. Tra i principali sviluppi si annoverano:
1. Maggiore specificità e copertura del proteoma grazie all'utilizzo di diagonal-PASEF.
2. Analisi del proteoma plasmatico profondo ad alta precisione da cento dollari.
3. Introduzione dell'analisi dei glicopeptidi plasmatici ad alta sensibilità sul timsTOF Ultra 2.
4. Incremento nell'identificazione di peptidi e proteine con TIMSrescore potenziato da ML.
5. Introduzione di visualizzazioni e approfondimenti multiomici per la proteomica e la metabolomica.
Questi avanzamenti permettono una proteomica robusta, imparziale e accessibile, con identificazione e quantificazione delle proteine ad alta specificità, adatta per studi di proteomica plasmatica su larga scala.
Bruker (Nasdaq: BRKR) anuncia avances significativos en 4D-Proteómica en el 23º Congreso Mundial de la Organización del Proteoma Humano. Los desarrollos clave incluyen:
1. Mayor especificidad y cobertura del proteoma utilizando diagonal-PASEF.
2. Logro de un análisis profundo del proteoma plasmático de cien dólares con alta precisión.
3. Introducción de análisis de glicopéptidos plasmáticos de alta sensibilidad en el timsTOF Ultra 2.
4. Aumento en la identificación de péptidos y proteínas con TIMSrescore mejorado por ML.
5. Introducción de visualización e información multiómica para la proteómica y la metabolómica.
Estos avances permiten una proteómica robusta, imparcial y asequible, con identificación y cuantificación de proteínas de alta especificidad, adecuada para estudios de proteómica plasmática a gran escala.
브루커 (Nasdaq: BRKR)는 제23회 인간 단백질체 조직 세계 총회에서 4D-단백질체학의 중요한 발전을 발표했습니다. 주요 발전 사항은 다음과 같습니다:
1. 대각선-PASEF를 활용하여 향상된 특이성과 단백질체 범위.
2. 높은 정확도의 100달러 심층 혈장 단백질체 분석 성과.
3. timsTOF Ultra 2에서의 고감도 혈장 글리코펩타이드 분석 도입.
4. ML 강화 TIMSrescore을 통한 펩타이드 및 단백질 식별 증가.
5. 단백질체학 및 대사체학을 위한 다중 오믹스 시각화 및 통찰력 도입.
이러한 발전은 높은 특이도의 단백질 식별 및 정량화가 가능한 강력하고 공정하며 저렴한 단백질체학을 가능하게 하여 대규모 혈장 단백질체 연구에 적합합니다.
Bruker (Nasdaq: BRKR) annonce des avancées significatives dans la 4D-Protéomique lors du 23e Congrès Mondial de l'Organisation du Protéome Humain. Les développements clés incluent :
1. Spécificité et couverture du protéome améliorées grâce à diagonal-PASEF.
2. Réalisation d'une analyse du protéome plasmatique profonde à 100 dollars avec une haute précision.
3. Introduction de l'analyse des glycopeptides plasmiques à haute sensibilité sur le timsTOF Ultra 2.
4. Augmentation de l'identification de peptides et de protéines avec TIMSrescore amélioré par IA.
5. Introduction de visualisations et d'aperçus multiomiques pour la protéomique et la métabolomique.
Ces avancées permettent une protéomique robuste, impartiale et abordable, avec une identification et une quantification des protéines d'une haute spécificité, adaptées aux études de protéomique plasmatique à grande échelle.
Bruker (Nasdaq: BRKR) kündigt bedeutende Fortschritte in der 4D-Proteomik auf dem 23. Weltkongress der Human Proteome Organization an. Zu den wichtigsten Entwicklungen gehören:
1. Verbesserte Spezifität und Proteomabdeckung durch diagonal-PASEF.
2. Erreichung einer hundert Dollar tiefen, hochgenauen Plasma-Proteom Analyse.
3. Einführung von hochsensitiver Plasma-Glykoproteinanalyse auf dem timsTOF Ultra 2.
4. Erhöhung der Peptid- und Proteinidentifikationen mit ML-verbessertem TIMSrescore.
5. Einführung von Multiomics-Visualisierung und Einblicken für Proteomik und Metabolomik.
Diese Fortschritte ermöglichen eine robuste, unvoreingenommene und kostengünstige Proteomik mit hochspezifischer Proteinidentifizierung und Quantifizierung, die sich für großangelegte Plasma-Proteomikstudien eignet.
- Introduction of diagonal-PASEF for enhanced specificity and proteome coverage
- Achievement of $100 deep, high-accuracy plasma proteome analysis, enabling large-scale studies
- Development of high-sensitivity plasma glycopeptide analysis on timsTOF Ultra 2
- Increased peptide and protein identifications with ML-enhanced TIMSrescore
- Introduction of multiomics visualization and insights for proteomics and metabolomics
- None.
Insights
Bruker 's announcement of advancements in 4D-Proteomics technology represents a significant leap in the field of proteomics, with potential long-term implications for the company's market position and revenue streams. The introduction of the one-hundred dollar, deep, high-accuracy plasma proteome is particularly noteworthy, as it could dramatically increase the accessibility and scalability of proteomics research.
Key financial implications include:
- Potential for increased market share in the proteomics instrumentation and consumables market
- New revenue opportunities from high-throughput, large-scale studies
- Competitive advantage in plasma proteomics, which could lead to expanded partnerships with pharmaceutical companies
- Possible increase in recurring revenue from consumables and software licenses
While the immediate financial impact may be , the long-term potential for growth in this high-value market is significant. Investors should monitor adoption rates and any subsequent increase in instrument sales or service contracts in the coming quarters.
Bruker's technological advancements in proteomics are groundbreaking for several reasons:
- The diagonal-PASEF method enhances specificity and proteome coverage, important for identifying rare or low-abundance proteins
- Achieving a one-hundred dollar deep plasma proteome analysis could revolutionize large-scale clinical studies and biomarker discovery
- Glyco-PASEF for glycoproteomics on the timsTOF Ultra 2 opens new avenues for studying protein modifications in disease states
- The ability to identify >100,000 peptides from human cell lines with low sample amounts is a significant improvement in sensitivity
These advancements could accelerate drug discovery, improve disease diagnostics and enable more personalized medicine approaches. The integration of proteomics with metabolomics and lipidomics in a multiomics platform further enhances the potential for comprehensive biological insights. This positions Bruker at the forefront of the proteomics field, potentially attracting more research funding and pharmaceutical partnerships.
- Robust, Unbiased and Affordable 4D-Proteomics™ for Highest-Specificity Protein IDs & Quant Enables High-Fidelity Large-Scale Plasma Proteomics
- Typical Sequence Coverage >10 Peptides/protein and >100k Peptides per Cell-Line Proteome Ushers in HiFi Proteomics with High Isoform Specificity
- Novel diagonal-PASEF® methods for immunopeptidomics and PTM characterization
-
Achieving
one-hundred-dollar high-fidelity plasma proteomics with PreOmics ENRICH™ and robust timsTOF HT acquisition for deep, unbiased plasma proteomics at scale with99% specificity (1% FDR)
In parallel, Biognosys introduces discovery services with P2 enrichment and Spectronaut® 19 for ultra-deep plasma proteomics with 7k or 9k identified proteins; optional integration of Alamar Bio ultra-high sensitivity NULISA® inflammation and CNS multiplex panels - Glyco-PASEF® acquisition, ENRICHplus and GlycoScape enable high-sensitivity plasma glycopeptide analysis on timsTOF Ultra 2
-
ML-enhanced TIMSrescore™ increases immunopeptidomics and PTM IDs; enables ultra-high-fidelity metaproteomics at
0.1% FDR (99.9% specificity) - Advancing 4D-Multiomics by combining proteomic, lipidomic and metabolomic insights
DRESDEN,
Bruker's timsTOF Ultra 2 Mass Spectrometer (Graphic: Business Wire)
A. Enhanced specificity and proteome coverage using diagonal-PASEF
Leveraging scanning quadrupole and trapped ion mobility spectrometry (TIMS), diagonal-PASEF was introduced in 2023 by key collaborators Dr. Matthias Mann (Max Planck Institute, Martinsried) and Dr. Stefan Tenzer (University of Mainz) to develop synchro-PASEF and midia-PASEF, respectively. Bruker and its partners now support all variants via Spectronaut 19, DIA-NN 1.9, MaxQuant 2.6.3, and midiaID.
Synchro-PASEF allows high-throughput acquisitions, while ensuring quantitative precision due to better sampling of ions, short cycle times, and up to 3-fold improved signal strength.
midia-PASEF offers higher-confidence immunopeptidomics and PTMs by extracting DDA-like spectra for de novo sequencing, and searches against very large databases.
Dr. Jarrod Marto, professor at Dana-Farber Cancer Institute, Harvard Medical School, participated in the midia-PASEF early-access program, and commented: “My lab leverages the timsTOF to understand how genomic alterations or small molecule probes manifest throughout the functional proteome. Our assessment is very positive, and we are now exploring the potential of midia-PASEF for quantitative analysis of post-translational modifications, as well as of MHC-associated peptides.”
B. Achievement of
Bruker spearheads deep, unbiased plasma proteome profiling with throughput, high peptide fidelity, and at enabling economics for large-scale studies. Together, PreOmics ENRICH-iST or ENRICHplus methods, robust and accurate (
Biopharma can access ultra-deep plasma proteome discovery with depth up to 7k proteins, or up to 9k at lower throughput, via research services offered by Biognosys, or by licensing proprietary P2 ultra-deep plasma enrichment for in-house use [Biognosys].
C. Introducing High-Sensitivity Plasma Glycopeptide Analysis on timsTOF Ultra 2
Bruker’s glyco-PASEF® for glycoproteomics has been optimized for the ultra-high sensitivity timsTOF Ultra 2 and human plasma samples. The new method incorporates ENRICHplus, resulting in a doubling of glycopeptides identified, and GlycoScape® data-base-independent software for integrated, deep glycobiology analysis.
D. Increased Peptide and Protein Identifications and ML-enhanced TIMSrescore
The timsTOF platform now routinely identifies much more than 100,000 peptides from human cell line proteomics with less than 1 µg loading in 20 minutes. High sequence coverage of typically >10 peptides/protein is critical for confident ID and quant, high isomer specificity, for detecting PTMs, as well as for immunopeptidomics and metaproteomics.
Bruker also is introducing TIMSrescore, developed with Dr. Lennart Martens’ team at the University of Ghent. Using ML for timsTOF collision cross-sections, retention time and fragment intensity, TIMSrescore increases high-confidence peptide IDs for dda-PASEF, relevant for PTMs and metaproteomics, where highest stringency (
Dr. Lennart Martens, Associate Director of Bioinformatics at the University of Ghent Center for Medical Biotechnology, stated: "My team and I are pleased with the enthusiastic uptake of TIMS2Rescore by our proteomics community. Through integration within Bruker ProteoScape software, we expand MS2rescore to timsTOF users, allowing our ML-based informatics to maximize the value of 4D-Proteomics.”
E. Introducing Multiomics Visualization and Insights for Proteomics and Metabolomics
Bruker ProteoScape™ now offers visualization and statistical analysis of 4D-Multiomics data from MetaboScape® for metabolomics and lipidomics. This enables dimensional reduction (such as PCA, LDA or t-SNE) and differential analysis, as well as intuitive visualizations, e.g., via interactive multiomics Volcano plots.
Dr. Roman Fischer, Associate Professor at University of Oxford, commented: “We utilize our timsTOFs for proteomics and lipidomics. The capabilities of ProteoScape and MetaboScape are impressive for real-time analysis to translate data into biological insights. It’s fantastic that Bruker now integrates both worlds with interactive multiomics visualization and statistical analysis.”
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241021537973/en/
Media
Petra Scheffer
Bruker Daltonics Marketing Communications
T: +49 (421) 2205-2843
E: petra.scheffer@bruker.com
Investor Relations
Joe Kostka
Associate Director, Investor Relations
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Source: Bruker Corporation
FAQ
What is the cost of Bruker's new deep, high-accuracy plasma proteome analysis?
How many proteins can be identified in ultra-deep plasma proteome discovery using Bruker's technology?
What is the specificity of protein identification in Bruker's new plasma proteomics technology?
How many peptides can Bruker's timsTOF platform identify from human cell line proteomics?
What is the new feature introduced in Bruker ProteoScape for multiomics analysis?
